Biogen Inc. (BIIB) stock
BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)
Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –
Biogen enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Biogen's enterprise value was $36.23B on Nov 11, 2026, against $22.72B a year earlier. Over the last 5 years it ranged from $15.74B to $45.19B, with a median of $30.79B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $36.23B | +66.0% |
| 2025 | Dec 31, 2025 | $21.82B | +5.8% |
| 2024 | Dec 31, 2024 | $20.62B | -41.6% |
| 2023 | Dec 29, 2023 | $35.29B | -1.0% |
| 2022 | Dec 30, 2022 | $35.66B | +5.5% |
| 2021 | Dec 31, 2021 | $33.78B | -9.6% |
| 2020 | Dec 31, 2020 | $37.38B | -29.2% |
| 2019 | Dec 31, 2019 | $52.82B | -9.3% |
| 2018 | Dec 31, 2018 | $58.22B | -13.4% |
| 2017 | Dec 29, 2017 | $67.26B | +11.7% |
| 2016 | Dec 30, 2016 | $60.23B | -11.3% |
| 2015 | Dec 31, 2015 | $67.92B | -14.5% |
| 2014 | Dec 31, 2014 | $79.43B | +19.9% |
| 2013 | Dec 31, 2013 | $66.25B | +89.7% |
| 2012 | Dec 31, 2012 | $34.92B | +26.6% |
| 2011 | Dec 30, 2011 | $27.59B | +42.2% |
| 2010 | Dec 31, 2010 | $19.41B | +27.0% |
| 2009 | Dec 31, 2009 | $15.29B | – |
See a number that looks wrong?